search
Back to results

Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy (CAREFOR)

Primary Purpose

Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Behavioral dietary intervention
Therapeutic conventional surgery
Radiation therapy
Counseling intervention
Quality-of-life assessment
Sponsored by
Sidney Kimmel Cancer Center at Thomas Jefferson University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ductal Breast Carcinoma in Situ

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Pathologically proven diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer
  2. Ability to have breast conservation as determined by the judgment of the radiation oncologist, for which the radiation oncologist has determined that he or she will only treat the whole breast and not regional lymph nodes
  3. The patient must be female
  4. Age >= 18
  5. If multifocal breast cancer, then it must be able to be resected through a single lumpectomy incision
  6. Appropriate stage for protocol entry, including no clinical evidence for distant metastases, based upon the following minimum diagnostic workup:

    1. History/physical examination, including breast exam and documentation of weight and Karnofsky performance status of 80-100% for at least 60 days prior to study entry
    2. Ipsilateral mammogram within 6 months prior to study entry
  7. Women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry
  8. Women of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during radiation therapy
  9. Patient must capable of and provide study specific informed consent prior to study entry
  10. Body mass index (BMI) >= 21
  11. Weight >= 100 lbs
  12. No prior history of non-breast malignancies in the past 2 years unless it was a non-melanomatous skin lesion or carcinoma in situ of the cervix
  13. Patient must not have any of the following severe, active co-morbidity, defined as follows:

    1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
    2. Transmural myocardial infarction within the last 6 months
    3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration
    5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol
    6. Acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV) positive based upon current Centers for Disease and Control (CDC) definition; note, however, that HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS or HIV from this protocol is necessary because anti-retrovirals may alter patient metabolism
  14. Patient must not have active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis with active rash
  15. No prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields
  16. Patient may not have any active gastrointestinal/malabsorption disorder at the discretion of the Principal Investigator

    1. Inflammatory bowel disease
    2. Celiac disease
    3. Chronic pancreatitis
    4. Chronic diarrhea or vomiting
    5. Active eating disorder
  17. Creatinine < 1.7
  18. Not currently taking steroids
  19. No currently active pituitary secreting tumors up to physician discretion
  20. No history of or current active drug/alcohol dependence
  21. No patients being decisionally impaired

Exclusion Criteria:

  1. Patient is not a candidate for breast conservation
  2. Patient is male
  3. Age < 18 years
  4. Patient requires regional lymph node irradiation therapy
  5. Patient has evidence of distant metastases
  6. Karnofsky performance status less than 80% within 60 days prior to study
  7. Ipsilateral mammogram done greater than 6 months prior to study
  8. Women of childbearing potential with a positive serum beta human chorionic gonadotropin (hCG)
  9. Patient has a history of dementia, psychosis or other disorder affecting their mental status to the point where they cannot consent or comply with study guidelines
  10. BMI < 21
  11. Weight < 100 lbs
  12. Weight loss >= 10% in the last 3 months (mos)
  13. Prior invasive non-breast malignancy (except non-melanomatous skin cancer, carcinoma in situ of the cervix) unless disease free for a minimum of 2 years prior to registration
  14. Two or more breast cancers not resectable through a single lumpectomy incision
  15. Non-epithelial breast malignancies such as sarcoma or lymphoma
  16. Prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields
  17. Severe, active co-morbidity, defined as follows:

    1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
    2. Transmural myocardial infarction within the last 6 months
    3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration
    5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol
    6. Acquired immune deficiency syndrome (AIDS) or HIV positive based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS or HIV from this protocol is necessary because anti-retrovirals may alter patient metabolism
  18. Active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis with active rash
  19. Active gastrointestinal/malabsorption disorder at the discretion of the Principal Investigator

    1. Inflammatory bowel disease
    2. Celiac disease
    3. Chronic pancreatitis
    4. Chronic diarrhea or vomiting
    5. Active eating disorder
  20. Creatinine >= 1.7
  21. Current use of steroids
  22. Pituitary secreting tumors up to physician discretion
  23. Active drug/alcohol dependence or abuse history
  24. Decisionally impaired patients

Sites / Locations

  • Thomas Jefferson University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Behavioral dietary intervention

Arm Description

Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.

Outcomes

Primary Outcome Measures

Number of Participants Who Are Adherent to the Diet Restriction
Computed along with a 95% exact confidence interval. Exact binomial test (with a one-sided alpha of 0.05) will be used to test whether adherence is greater than 60%.

Secondary Outcome Measures

Change in Body Fat Measurement
Analyzed via a paired t-test. Change in body fat measurement as determined by the Durnin-Womersley 4-fold technique
Change in Body Mass Index (BMI)
Assessed via mixed-effects regression. Weight changes over time assessed by modeling BMI as a function of time
Change in Heart Rate Over Time
Assessed via mixed-effects regression.
Patterns of Change Over Time in Serum Markers
Assessed via mixed-effects regression.
Patterns of Change Over Time in Psycho-social Outcomes Measured Using the Functional Assessment of Cancer Therapy-Breast (FACT-B)
Assessed via mixed-effects regression. The FACT-B is a questionnaire using a 5-point Likert scale (0-Not at all to 4-Very much)
Local Recurrence
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.
Distant Metastases
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.
Progression Free Survival
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.
Overall Survival
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.

Full Information

First Posted
March 22, 2013
Last Updated
December 4, 2019
Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
search

1. Study Identification

Unique Protocol Identification Number
NCT01819233
Brief Title
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
Acronym
CAREFOR
Official Title
A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
March 8, 2013 (Actual)
Primary Completion Date
September 14, 2017 (Actual)
Study Completion Date
September 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This pilot clinical trial studies caloric restriction in patients with stage 0-I breast cancer during surgery and radiation therapy. Reducing caloric intake may prevent disease progression in patients with breast cancer. Radiation therapy uses high energy x rays to kill tumor cells. Giving dietary intervention and radiation therapy together may kill more tumor cells.
Detailed Description
PRIMARY OBJECTIVE: Investigate the feasibility of a clinical trial administering ionizing radiation with concurrent caloric restriction (CR) for the treatment of breast cancer. SECONDARY OBJECTIVE: Investigate measurable changes of patient characteristics and tissue and serum from CR conditions to determine a metric for evaluating this treatment in future studies. OUTLINE: Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy once daily (QD) 5 days a week for 6 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Lobular Breast Carcinoma in Situ, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
38 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Behavioral dietary intervention
Arm Type
Experimental
Arm Description
Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.
Intervention Type
Behavioral
Intervention Name(s)
Behavioral dietary intervention
Intervention Description
Receive caloric restricted dietary intervention
Intervention Type
Procedure
Intervention Name(s)
Therapeutic conventional surgery
Intervention Description
Undergo definitive lumpectomy
Intervention Type
Radiation
Intervention Name(s)
Radiation therapy
Other Intervention Name(s)
Irradiation, Radiotherapy, Radiation
Intervention Description
Undergo radiation therapy
Intervention Type
Other
Intervention Name(s)
Counseling intervention
Other Intervention Name(s)
Counseling and communications studies
Intervention Description
Receive dietary counseling
Intervention Type
Procedure
Intervention Name(s)
Quality-of-life assessment
Other Intervention Name(s)
Quality of life assessment
Intervention Description
Ancillary studies
Primary Outcome Measure Information:
Title
Number of Participants Who Are Adherent to the Diet Restriction
Description
Computed along with a 95% exact confidence interval. Exact binomial test (with a one-sided alpha of 0.05) will be used to test whether adherence is greater than 60%.
Time Frame
Up to week 12
Secondary Outcome Measure Information:
Title
Change in Body Fat Measurement
Description
Analyzed via a paired t-test. Change in body fat measurement as determined by the Durnin-Womersley 4-fold technique
Time Frame
Baseline to 4 weeks after completion of study
Title
Change in Body Mass Index (BMI)
Description
Assessed via mixed-effects regression. Weight changes over time assessed by modeling BMI as a function of time
Time Frame
Baseline to 4 weeks after completion of study
Title
Change in Heart Rate Over Time
Description
Assessed via mixed-effects regression.
Time Frame
Baseline to 4 weeks after completion of study
Title
Patterns of Change Over Time in Serum Markers
Description
Assessed via mixed-effects regression.
Time Frame
Baseline to 4 weeks after completion of study
Title
Patterns of Change Over Time in Psycho-social Outcomes Measured Using the Functional Assessment of Cancer Therapy-Breast (FACT-B)
Description
Assessed via mixed-effects regression. The FACT-B is a questionnaire using a 5-point Likert scale (0-Not at all to 4-Very much)
Time Frame
Baseline to 4 weeks after completion of study
Title
Local Recurrence
Description
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.
Time Frame
Up to 4 weeks after completion of study
Title
Distant Metastases
Description
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.
Time Frame
Up to 4 weeks after completion of study
Title
Progression Free Survival
Description
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.
Time Frame
Up to 4 weeks after completion of study
Title
Overall Survival
Description
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.
Time Frame
Up to 4 weeks after completion of study

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pathologically proven diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer Ability to have breast conservation as determined by the judgment of the radiation oncologist, for which the radiation oncologist has determined that he or she will only treat the whole breast and not regional lymph nodes The patient must be female Age >= 18 If multifocal breast cancer, then it must be able to be resected through a single lumpectomy incision Appropriate stage for protocol entry, including no clinical evidence for distant metastases, based upon the following minimum diagnostic workup: History/physical examination, including breast exam and documentation of weight and Karnofsky performance status of 80-100% for at least 60 days prior to study entry Ipsilateral mammogram within 6 months prior to study entry Women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry Women of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during radiation therapy Patient must capable of and provide study specific informed consent prior to study entry Body mass index (BMI) >= 21 Weight >= 100 lbs No prior history of non-breast malignancies in the past 2 years unless it was a non-melanomatous skin lesion or carcinoma in situ of the cervix Patient must not have any of the following severe, active co-morbidity, defined as follows: Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months Transmural myocardial infarction within the last 6 months Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol Acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV) positive based upon current Centers for Disease and Control (CDC) definition; note, however, that HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS or HIV from this protocol is necessary because anti-retrovirals may alter patient metabolism Patient must not have active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis with active rash No prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields Patient may not have any active gastrointestinal/malabsorption disorder at the discretion of the Principal Investigator Inflammatory bowel disease Celiac disease Chronic pancreatitis Chronic diarrhea or vomiting Active eating disorder Creatinine < 1.7 Not currently taking steroids No currently active pituitary secreting tumors up to physician discretion No history of or current active drug/alcohol dependence No patients being decisionally impaired Exclusion Criteria: Patient is not a candidate for breast conservation Patient is male Age < 18 years Patient requires regional lymph node irradiation therapy Patient has evidence of distant metastases Karnofsky performance status less than 80% within 60 days prior to study Ipsilateral mammogram done greater than 6 months prior to study Women of childbearing potential with a positive serum beta human chorionic gonadotropin (hCG) Patient has a history of dementia, psychosis or other disorder affecting their mental status to the point where they cannot consent or comply with study guidelines BMI < 21 Weight < 100 lbs Weight loss >= 10% in the last 3 months (mos) Prior invasive non-breast malignancy (except non-melanomatous skin cancer, carcinoma in situ of the cervix) unless disease free for a minimum of 2 years prior to registration Two or more breast cancers not resectable through a single lumpectomy incision Non-epithelial breast malignancies such as sarcoma or lymphoma Prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields Severe, active co-morbidity, defined as follows: Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months Transmural myocardial infarction within the last 6 months Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol Acquired immune deficiency syndrome (AIDS) or HIV positive based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS or HIV from this protocol is necessary because anti-retrovirals may alter patient metabolism Active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis with active rash Active gastrointestinal/malabsorption disorder at the discretion of the Principal Investigator Inflammatory bowel disease Celiac disease Chronic pancreatitis Chronic diarrhea or vomiting Active eating disorder Creatinine >= 1.7 Current use of steroids Pituitary secreting tumors up to physician discretion Active drug/alcohol dependence or abuse history Decisionally impaired patients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicole Simone, MD
Organizational Affiliation
Thomas Jefferson University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Thomas Jefferson University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
20097433
Citation
Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci. 2010 Feb;31(2):89-98. doi: 10.1016/j.tips.2009.11.004. Epub 2010 Jan 25.
Results Reference
background
PubMed Identifier
12525670
Citation
Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med. 2003;54:131-52. doi: 10.1146/annurev.med.54.101601.152156. Epub 2001 Dec 3.
Results Reference
background
PubMed Identifier
19867833
Citation
Rous P. THE INFLUENCE OF DIET ON TRANSPLANTED AND SPONTANEOUS MOUSE TUMORS. J Exp Med. 1914 Nov 1;20(5):433-51. doi: 10.1084/jem.20.5.433.
Results Reference
background
Citation
Tannenbaum A. Effects of Varying Caloric Intake Upon Tumor Incidence and Tumor Growth. Annals of the New York Academy of Sciences. 15 Dec 2006 2006;49(1).
Results Reference
background
PubMed Identifier
12016155
Citation
Berrigan D, Perkins SN, Haines DC, Hursting SD. Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. Carcinogenesis. 2002 May;23(5):817-22. doi: 10.1093/carcin/23.5.817.
Results Reference
background
PubMed Identifier
10469616
Citation
Zhu Z, Jiang W, Thompson HJ. Effect of energy restriction on tissue size regulation during chemically induced mammary carcinogenesis. Carcinogenesis. 1999 Sep;20(9):1721-6. doi: 10.1093/carcin/20.9.1721.
Results Reference
background
PubMed Identifier
2337899
Citation
Lok E, Scott FW, Mongeau R, Nera EA, Malcolm S, Clayson DB. Calorie restriction and cellular proliferation in various tissues of the female Swiss Webster mouse. Cancer Lett. 1990 May 15;51(1):67-73. doi: 10.1016/0304-3835(90)90232-m.
Results Reference
background
PubMed Identifier
7937932
Citation
Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, Wagner A, Lauer B, Schulte-Hermann R. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9995-9. doi: 10.1073/pnas.91.21.9995.
Results Reference
background
PubMed Identifier
9242428
Citation
Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R, Glazer PM. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997 Aug 1;57(15):3079-83.
Results Reference
background
PubMed Identifier
11038295
Citation
Perer ES, Madan AK, Shurin A, Zakris E, Romeguera K, Pang Y, Beech DJ. Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res. 2000 Nov;94(1):1-5. doi: 10.1006/jsre.2000.5923.
Results Reference
background
PubMed Identifier
21696633
Citation
Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr. 2011 Jun 22;3:12. doi: 10.1186/1758-5996-3-12.
Results Reference
background
PubMed Identifier
17167471
Citation
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006 Dec 14;444(7121):840-6. doi: 10.1038/nature05482.
Results Reference
background
PubMed Identifier
20145127
Citation
Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010 Feb 15;70(4):1564-72. doi: 10.1158/0008-5472.CAN-09-3228. Epub 2010 Feb 9.
Results Reference
background
PubMed Identifier
22984531
Citation
Safdie F, Brandhorst S, Wei M, Wang W, Lee C, Hwang S, Conti PS, Chen TC, Longo VD. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One. 2012;7(9):e44603. doi: 10.1371/journal.pone.0044603. Epub 2012 Sep 11.
Results Reference
background
Citation
National Institutes of Health. http://www.clincaltrials.gov.
Results Reference
background
PubMed Identifier
22735163
Citation
Arguin H, Dionne IJ, Senechal M, Bouchard DR, Carpentier AC, Ardilouze JL, Tremblay A, Leblanc C, Brochu M. Short- and long-term effects of continuous versus intermittent restrictive diet approaches on body composition and the metabolic profile in overweight and obese postmenopausal women: a pilot study. Menopause. 2012 Aug;19(8):870-6. doi: 10.1097/gme.0b013e318250a287.
Results Reference
background
Links:
URL
http://www.JeffersonHospital.org
Description
Thomas Jefferson University Hospitals

Learn more about this trial

Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy

We'll reach out to this number within 24 hrs